Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
₹12 Cr
Revenue (TTM)
₹0 Cr
Net Profit (TTM)
₹-1 Cr
ROE
-35.3 %
ROCE
-24.4 %
P/E Ratio
--
P/B Ratio
9.2
Industry P/E
44.74
EV/EBITDA
-13.9
Div. Yield
0 %
Debt to Equity
0.1
Book Value
₹1.5
EPS
₹-1.1
Face value
10
Shares outstanding
8,131,392
CFO
₹28.57 Cr
EBITDA
₹23.29 Cr
Net Profit
₹-5.70 Cr
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Ortin Laboratories
| 2.9 | -17.3 | 3.0 | 38.1 | -6.8 | -13.6 | -3.1 |
|
BSE Healthcare
| -4.7 | -5.8 | -5.4 | 1.3 | 23.7 | 14.0 | 10.6 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
|---|---|---|---|---|---|---|---|
|
Ortin Laboratories
| -22.7 | -21.8 | -2.7 | -28.7 | -46.1 | 200.5 | -35.1 |
|
BSE Small Cap
| -6.6 | 29.0 | 47.5 | -1.8 | 62.8 | 32.1 | -6.8 |
|
BSE Healthcare
| -3.3 | 43.1 | 37.0 | -12.1 | 20.9 | 61.4 | -3.5 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price (₹) | Market Cap (₹ Cr) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Ortin Laboratories
|
14.2 | 11.6 | 0.2 | -0.9 | -452.8 | -54.5 | -- | 9.2 |
| 2,110.2 | 17,282.6 | 1,215.1 | 284.8 | 28.7 | 21.1 | 60.2 | 11.4 | |
| 656.2 | 12,893.6 | 7,266.8 | 627.5 | 11.9 | 12.6 | 20.5 | 2.4 | |
| 613.6 | 15,214.7 | 5,092.5 | 545.5 | 15.9 | 14.1 | 27.9 | 3.7 | |
| 839.3 | 13,375.6 | 7,918.4 | 429.9 | 10.7 | 7.2 | 30.9 | 2.0 | |
| 1,027.6 | 18,409.8 | 4,560.2 | 1,544.6 | 35.1 | 19.2 | 11.8 | 2.1 | |
| 1,404.5 | 16,092.2 | 1,419.3 | 20.1 | 8.4 | 0.5 | 800.5 | 2.8 | |
| 142.2 | 18,882.0 | 8,871.4 | -223.5 | 1.9 | -1.6 | -- | 2.4 | |
| 391.1 | 15,752.9 | 3,720.2 | 352.1 | 13.7 | 8.2 | 44.7 | 3.3 | |
| 1,271.5 | 20,670.6 | 3,151.0 | -10.0 | 8.4 | 2.5 | 939.6 | 4.5 |
No Review & Analysis are available.
Ortin Global Limited engages in the manufacture and trading of pharmaceuticals, drugs, and intermediates in India. The company offers various pharmaceutical formulations of tablets, capsules, syrups, and dry powders; formulations, such as... anti-diabetics, anti-allergics, anti-anginal and cardiovascular, sedatives and tranquilisers, anti-helmenthetics, analgesics and antipyretics, anti-biotics-quinolones, anti-biotic-pencillins, antifungal, cephalosporins, and macrolides. Its formulations also include chemo therapeutics, antacids and anti-ulcerants, anti-spasmodics, calcium and iron preparations, anti-arthritic drugs, protein supplements, enzymes, and vitamins, as well as psychiatry, appetizer, gynaec, and anti-retroviral products. In addition, the company offers active pharmaceutical ingredient (API) intermediates, including anti-retroviral, anti-diabetics, analgesics and antipyretics, anti-biotics, antifungal, antacids and anti-ulcerants, and anti-malarials; and manufactures fine chemicals, and grignard and alkali metal products. Further, the company provides services in the areas of process development, process and product characterization, analytical research and development, and assay development; research and development services for new formulation brands; and diagnostic services comprising development of rapid flow kits, assays, and reagents. Additionally, it undertakes long-term contracts for manufacturing intermediates and developing new APIs; operates as a merchant exporter of pharmaceutical finished formulations; and engages in real estate. The company was formerly known as Ortin Laboratories Limited and changed its name to Ortin Global Limited in June 2024. Ortin Global Limited was incorporated in 1986 and is headquartered in Hyderabad, India. Read more
Incorporated
1986
Chairman
Sarang Balbhimrao Patodekar
Managing Director
Murali Krishna Murthy Sanka
Headquarters
Hyderabad, Telangana
Website
Our rating system has guided millions of investors in the past 20 years.
Annual Reports
Announcements
View AnnouncementsCorrigendum to Detailed Public Statement
27-Feb-2026Corrigendum to the Public Announcement
14-Feb-2026Public Announcement - Open Offer
11-Feb-2026
The share price of Ortin Laboratories Ltd is ₹14.21 (NSE) and ₹13.73 (BSE) as of 02-Apr-2026 IST. Ortin Laboratories Ltd has given a return of -6.8% in the last 3 years.
Since, TTM earnings of Ortin Laboratories Ltd is negative, P/E ratio is not available.
The P/B ratio of Ortin Laboratories Ltd is 9.25 times as on 02-Apr-2026, a 198 premium to its peers’ median range of 3.10 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2025
|
0.00
|
4.10
|
|
2024
|
0.00
|
5.13
|
|
2023
|
0.00
|
1.30
|
|
2022
|
0.00
|
1.68
|
|
2021
|
27.74
|
2.31
|
The 52-week high and low of Ortin Laboratories Ltd are Rs 19.90 and Rs 9.93 as of 04-Apr-2026.
Ortin Laboratories Ltd has a market capitalisation of ₹ 12 Cr as on 02-Apr-2026. As per SEBI classification, it is a Small Cap company.
Before investing in Ortin Laboratories Ltd, assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
₹-0.02
(
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.